Ger­man biotech’s ef­forts to re­vive obe­si­ty tar­get for sol­id tu­mors yield pos­i­tive PhI­Ia re­sults

CatalYm’s sol­id tu­mor can­di­date, which tar­gets a pro­tein pre­vi­ous­ly ex­plored in obe­si­ty, has boost­ed re­spons­es in com­bi­na­tion with an im­mune check­point in­hibitor in an ear­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER